K-CAB Surge and Vaccine Distribution Put HK inno.N on the Verge of ₩1 Trillion in Annual Sales
HK inno.N is closing in on its first-ever annual sales of ₩1 trillion. According to financial data provider…
K-Cab
4 개의 기사가 있습니다.
HK inno.N's K-Cab Expands into the Oceania Market
HK inno.N's gastroesophageal reflux disease (GERD) drug, K-Cab, is expanding into the Australian and New Zealand markets. On…
HK inno.N's K-CAB Receives Approval in Malaysia
HK inno.N's novel drug for gastroesophageal reflux disease (GERD), K-CAB, has received marketing approval in Malaysia. HK inno.N…
Reasons to Watch HK Inno.N in the Second Half of the Year
HK Inno.N Corporation is emerging as a company to watch in the second half of the year, following…